Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Leifer

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trialsClaire Vale, Peter J Godolphin, David Fisher, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2024
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional TrialJason G Dehn, Brent Logan, Bronwen E Shaw, et al.
Blood Advances|June 9, 2026
Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment TrialAsad Bashey, Brent R Logan, LaQuisa C Hill, et al.
Transplantation and Cellular Therapy|November 10, 2025
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 TrialJason G Dehn, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy|January 17, 2026
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trialJoseph Pidala, Brent Logan, Stephanie J Lee, et al.
Chest|November 18, 2023
Symptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial: Effect on 3-Month Symptoms and Quality of LifeYonatan Y Greenstein, Kinsley Hubel, Joshua Froess, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trialsClaire Vale, Peter J Godolphin, David Fisher, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2024
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional TrialJason G Dehn, Brent Logan, Bronwen E Shaw, et al.
Blood Advances|June 9, 2026
Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment TrialAsad Bashey, Brent R Logan, LaQuisa C Hill, et al.
Transplantation and Cellular Therapy|November 10, 2025
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 TrialJason G Dehn, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy|January 17, 2026
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trialJoseph Pidala, Brent Logan, Stephanie J Lee, et al.
Chest|November 18, 2023
Symptoms and Impaired Quality of Life After COVID-19 Hospitalization: Effect of Therapeutic Heparin in Non-ICU Patients in the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute Trial: Effect on 3-Month Symptoms and Quality of LifeYonatan Y Greenstein, Kinsley Hubel, Joshua Froess, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.
Pageof 5